Hepatic Gluconeogenic Response to Single and Long-Term SGLT2 Inhibition in Lean/Obese Male Hepatic G6pc-Reporter Mice
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) consistently reduces blood glucose levels in type 2 diabetes mellitus but increases hepatic gluconeogenic gene expression and glucose production, offsetting its glucose-lowering effect. This study aimed to elucidate the effect of SGLT2i on hepatic gluconeogenic response and its mechanism in both insulin-sensitive and insulin-resistant states. A hepatic mouse model was generated to show liver-specific expression of Gaussia luciferase (GLuc) driven by the gluconeogenic enzyme gene G6pc promoter. Hepatic gluconeogenic response was evaluated by measuring plasma GLuc activity. SGLT2i was given to lean and obese mice in single gavage administration or 4-week dietary administration with controlled feeding every 3 hours. In lean mice, single-dose SGLT2i increased plasma GLuc activity from 2 hours after administration, decreasing blood glucose and plasma insulin from 1 to 2 hours after administration. In obese mice, which had higher plasma GLuc activity than lean ones, SGLT2i did not further increase GLuc activity despite decreased blood glucose and plasma insulin. Hepatic Akt and GSK3β phosphorylation was attenuated by single-dose SGLT2i in lean mice in accordance with the plasma insulin decrease, but not in obese mice. Long-term SGLT2i administration, which increased plasma GLuc activity in lean mice, decreased it in obese mice from 3 weeks after initiation, with increased hepatic Akt and GSK3β phosphorylation. In conclusion, single SGLT2i administration increases hepatic gluconeogenic response in lean insulin-sensitive mice, but not in obese insulin-resistant mice. Long-term SGLT2i administration relieves obesity-induced upregulation of the hepatic gluconeogenic response by restoring impeded hepatic insulin signaling in obese insulin-resistant mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SGLT2 inhibition reduced GSK3-β activity in hepatocytes [121].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [121]
Citations
Cites
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
Normal growth and development in the absence of hepatic insulin-like growth factor I
Yakar, S., Liu, J.-L., Stannard, B., Butler, A., Accili, D., Sauer, B., & LeRoith, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7324 · Cited by 1,420
The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes
Perry, R. J., Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2014) · Nature · doi:10.1038/nature13478 · Cited by 1,136
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Regulation of hepatic glucose metabolism in health and disease
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.80 · Cited by 1,133
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Magnusson, I., Rothman, D. L., Katz, L. D., Shulman, R. G., & Shulman, G. I. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115997 · Cited by 757
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Insulin regulation of gluconeogenesis
Hatting, M., Tavares, C. D. J., Sharabi, K., Rines, A. K., & Puigserver, P. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13435 · Cited by 587
Cited by
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
Wilson, P. C., Muto, Y., Wu, H., Karihaloo, A., Waikar, S. S., & Humphreys, B. D. (2022) · Nature Communications · doi:10.1038/s41467-022-32972-z · Cited by 193
Packer, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1732 · Cited by 105
Armillotta, M., Angeli, F., Paolisso, P., Belmonte, M., Raschi, E., Dalmazi, G. D., Amicone, S., Canton, L., Fedele, D., Suma, N., et al. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108861 · Cited by 84
Inaba, Y., Hashiuchi, E., Watanabe, H., Kimura, K., Oshima, Y., Tsuchiya, K., Murai, S., Takahashi, C., Matsumoto, M., Kitajima, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35804-w · Cited by 68
Self-citation
Metadata
- Authors
- Inaba, Y., Hashiuchi, E., Watanabe, H., Kimura, K., Sato, M., Kobayashi, M., Matsumoto, M., Kitamura, T., Kasuga, M., & Inoue, H.
- Affiliations
- Kanazawa University (JP)
- Gunma University (JP)
- National Center for Global Health and Medicine (JP)
- The Institute of Medical Science, Asahi Life Foundation (JP)
- Corresponding author
- Inaba, Yuka
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2019-09-13
- Volume
- 160
- Issue
- 12
- Pages
- 2811-2824
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2972690122
- Cited by
- 18
- References
- 31
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 1
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (17H05499, 18KT0020, 15H05678)
- Taisho Toyama Pharmaceutical Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- SGLT2 inhibitors, hepatic gluconeogenesis, glucose-6-phosphatase, hepatic insulin signaling, Akt phosphorylation, GSK3β phosphorylation, obesity, insulin resistance, type 2 diabetes, blood glucose, hepatic glucose production
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Gluconeogenesis, Glucose-6-Phosphatase, Insulin, Insulin Resistance, Liver, Male, Mice, Inbred C57BL, Obesity, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatic Gluconeogenic Response to Single and Long-Term SGLT2 Inhibition in Lean/Obese Male Hepatic G6pc-Reporter Mice. https://app.cochat.ai/papers/10.1210/en.2019-00422
- The paper
- Inaba, Y., Hashiuchi, E., Watanabe, H., Kimura, K., Sato, M., Kobayashi, M., Matsumoto, M., Kitamura, T., Kasuga, M., & Inoue, H. (2019). Hepatic Gluconeogenic Response to Single and Long-Term SGLT2 Inhibition in Lean/Obese Male Hepatic G6pc-Reporter Mice. Endocrinology. https://doi.org/10.1210/en.2019-00422
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.